{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:11:00Z","timestamp":1788667860512,"version":"build-2803163510"},"reference-count":51,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Cybin Inc"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Serotonergic psychedelics, such as\n                      <jats:italic toggle=\"yes\">N,N<\/jats:italic>\n                      -dimethyltryptamine (DMT), have shown therapeutic potential in various psychiatric disorders. However, DMT demonstrates pharmacokinetic (PK) variability and a short half-life.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>This exploratory study investigated the PK, pharmacodynamic (PD), and safety profile of CYB004, a deuterated DMT analogue, following intravenous administration in healthy volunteers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>CYB004, a deuterated DMT analogue, was evaluated in a randomized, double-blind, placebo-controlled, two-part study in healthy participants. Part 1 was a single-dose cohort, in which participants received a 5-minute intravenous 12.7\u2009mg CYB004 bolus, followed by a 30-minute 15.41\u2009mg infusion. Part 2 was a three-way crossover, during which two separate 5-minute 12.7\u2009mg CYB004 boluses were administered. Outcome measures included PK of CYB004 and subjective, autonomic, neurophysiological, and adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Although high CYB004 doses led to intense psychedelic experiences and participant withdrawals, lower doses achieving plasma concentrations similar to those in previous DMT studies demonstrated an acceptable safety profile. CYB004 demonstrated a PD profile that was similar to DMT at comparable plasma concentrations. PD effects consisted of subjective psychedelic effects, electroencephalography power band reductions, and autonomic nervous system activation. CYB004\u2019s half-life was approximately two-fold longer than DMT, prolonging the duration of psychedelic effects to ~40\u201360\u2009minutes following brief intravenous administration. However, deuteration did not improve PK variability, with IV-administered CYB004 demonstrating moderate to high variability, largely driven by interindividual differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>CYB004 demonstrated PD effects comparable to DMT. However, CYB004 demonstrated an extended duration of these effects due to reduced clearance, while maintaining an acceptable safety profile at clinically relevant exposures despite PK variability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261478616","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:06:40Z","timestamp":1788433600000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety, pharmacokinetics, and pharmacodynamics of intravenously administered deuterated\n                    <i>N,N<\/i>\n                    -dimethyltryptamine (CYB004) in healthy volunteers"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1783-357X","authenticated-orcid":false,"given":"Katelijne V.","family":"van der Heijden","sequence":"first","affiliation":[{"name":"Centre for Human Drug Research, Leiden, the Netherlands"},{"name":"Leiden University Medical Center, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5140-9450","authenticated-orcid":false,"given":"Gabriel E.","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, the Netherlands"},{"name":"Department of Psychiatry, Leiden University Medical Center, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9554-573X","authenticated-orcid":false,"given":"Ellen H.","family":"James","sequence":"additional","affiliation":[{"name":"Cybin IRL Limited, a Wholly Owned Subsidiary of Helus Pharma Corp, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep J.","family":"Nathan","sequence":"additional","affiliation":[{"name":"Cybin IRL Limited, a Wholly Owned Subsidiary of Helus Pharma Corp, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije E.","family":"Otto","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, the Netherlands"},{"name":"Leiden Academic Centre for Drug Research, Leiden University, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5280-4377","authenticated-orcid":false,"given":"Roman","family":"Bohoslavsky","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke L.","family":"de Kam","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop M. A.","family":"van Gerven","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, the Netherlands"},{"name":"Leiden University Medical Center, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3310-2735","authenticated-orcid":false,"given":"Amir","family":"Inamdar","sequence":"additional","affiliation":[{"name":"Cybin IRL Limited, a Wholly Owned Subsidiary of Helus Pharma Corp, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"crossref","unstructured":"Ansara ED (2020) Management of treatment-resistant generalized anxiety disorder. The Mental Health Clinician 10(6): 326\u2013334. https:\/\/doi.org\/10.9740\/mhc.2020.11.326","DOI":"10.9740\/mhc.2020.11.326"},{"key":"e_1_3_2_3_1","doi-asserted-by":"crossref","unstructured":"Barrett FS Johnson MW Griffiths RR (2015) Validation of the revised Mystical Experience Questionnaire inexperimental sessions with psilocybin. Journal of Psychopharmacology 29: 1182\u20131190. https:\/\/doi.org\/10.1177\/0269881115609019","DOI":"10.1177\/0269881115609019"},{"key":"e_1_3_2_4_1","volume-title":"Konstruktion des Fragebogens OAV zut quantitativen Erfassung au\u03b2ergew\u00f6hnlicher Bewu\u03b2tseinszust\u00e4nde","author":"Bodmer I","year":"1989","unstructured":"Bodmer I (1989) Konstruktion des Fragebogens OAV zut quantitativen Erfassung au\u03b2ergew\u00f6hnlicher Bewu\u03b2tseinszust\u00e4nde [Construction of the OAV questionnaire for the quantitative assessment of extraordinary states of consciousness] (ABZ). University of Zurich."},{"key":"e_1_3_2_5_1","doi-asserted-by":"crossref","unstructured":"Bond A Lader M (1974) The use of analogue scales in rating subjective feelings. British Journal of Medical Psychology 47(3): 211\u2013218. https:\/\/doi.org\/10.1111\/j.2044-8341.1974.tb02285.x","DOI":"10.1111\/j.2044-8341.1974.tb02285.x"},{"key":"e_1_3_2_6_1","doi-asserted-by":"crossref","unstructured":"Carhart-Harris R Giribaldi B Watts R et al. (2021) Trial of psilocybin versus escitalopram for depression. The New England Journal of Medicine 384(15): 1402\u20131411. https:\/\/doi.org\/10.1056\/NEJMoa2032994","DOI":"10.1056\/NEJMoa2032994"},{"key":"e_1_3_2_7_1","doi-asserted-by":"crossref","unstructured":"Chen X de Haas S de Kam M et al. (2012) An overview of the CNS-pharmacodynamic profiles of nonselective and selective GABA agonists. Advances in Pharmacological Sciences 2012: 134523. https:\/\/doi.org\/10.1155\/2012\/134523","DOI":"10.1155\/2012\/134523"},{"key":"e_1_3_2_8_1","doi-asserted-by":"crossref","unstructured":"Cybin UK Ltd (2024) Safety tolerability pharmacokinetics (PK) pharmacodynamics (PD) and effects of intravenous (IV) and intramuscular (IM) dosing of SPL028 (deuterated DMT fumarate [a serotonergic psychedelic]) in healthy volunteers and participants with major depressive. ISRCTN (ISRCTN42293056). https:\/\/doi.org\/10.1186\/ISRCTN42293056","DOI":"10.1186\/ISRCTN42293056"},{"key":"e_1_3_2_9_1","doi-asserted-by":"crossref","unstructured":"Davis AK Barrett FS May DG et al. (2021) Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry 78(5): 481\u2013489. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285","DOI":"10.1001\/jamapsychiatry.2020.3285"},{"key":"e_1_3_2_10_1","doi-asserted-by":"crossref","unstructured":"D\u2019Souza DC Syed SA Flynn LT et al. (2022) Exploratory study of the dose-related safety tolerability and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacology 47(10): 1854\u20131862. https:\/\/doi.org\/10.1038\/s41386-022-01344-y","DOI":"10.1038\/s41386-022-01344-y"},{"key":"e_1_3_2_11_1","article-title":"Simple, automatic noncompartmental analysis: The PKNCA R package","volume":"42","author":"Denney WS","year":"2015","unstructured":"Denney WS, Duvvuri S, Buckeridge C (2015) Simple, automatic noncompartmental analysis: The PKNCA R package. Journal of Pharmacokinetics and Pharmacodynamics 42: S65\u2013S65.","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"key":"e_1_3_2_12_1","doi-asserted-by":"crossref","unstructured":"de Visser SJ van der Post J Pieters MS et al. (2001) Biomarkers for the effects of antipsychotic drugs in healthy volunteers. British Journal of Clinical Pharmacology 51(2): 119\u2013132. https:\/\/doi.org\/10.1111\/j.1365-2125.2001.01308.x","DOI":"10.1111\/j.1365-2125.2001.01308.x"},{"key":"e_1_3_2_13_1","doi-asserted-by":"crossref","unstructured":"Di Martino RMC Maxwell BD Pirali T (2023) Deuterium in drug discovery: Progress opportunities and challenges. Nature Reviews Drug Discovery 22(7): 562\u2013584. https:\/\/doi.org\/10.1038\/s41573-023-00703-8","DOI":"10.1038\/s41573-023-00703-8"},{"key":"e_1_3_2_14_1","doi-asserted-by":"crossref","unstructured":"Dornbierer DA Marten L Mueller J et al. (2023) Overcoming the clinical challenges of traditional ayahuasca: A first-in-human trial exploring novel routes of administration of N N-Dimethyltryptamine and harmine. Frontiers in Pharmacology 14: 1246892. https:\/\/doi.org\/10.3389\/fphar.2023.1246892","DOI":"10.3389\/fphar.2023.1246892"},{"key":"e_1_3_2_15_1","doi-asserted-by":"crossref","unstructured":"Dunkley EJC Isbister GK Sibbritt D et al. (2003) The hunter serotonin toxicity criteria: Aimple and accurate diagnostic decision rules for serotonin toxicity. QJM: An International Journal of Medicine 96(9): 635\u2013642. https:\/\/doi.org\/10.1093\/qjmed\/hcg109","DOI":"10.1093\/qjmed\/hcg109"},{"key":"e_1_3_2_16_1","doi-asserted-by":"crossref","unstructured":"Eckern\u00e4s E Timmermann C Carhart-Harris R et al. (2022) Population pharmacokinetic\/pharmacodynamic modeling of the psychedelic experience induced by N N-dimethyltryptamine\u2014Implications for dose considerations. Clinical and Translational Science 15(12): 2928\u20132937. https:\/\/doi.org\/10.1111\/cts.13410","DOI":"10.1111\/cts.13410"},{"key":"e_1_3_2_17_1","doi-asserted-by":"crossref","unstructured":"Erne L Vogt SB M\u00fcller L et al. (2024) Acute dose-dependent effects and self-guided titration of continuous N N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants. Neuropsychopharmacology 50(6):1008\u20131016. https:\/\/doi.org\/10.1038\/s41386-024-02041-8","DOI":"10.1038\/s41386-024-02041-8"},{"key":"e_1_3_2_18_1","doi-asserted-by":"crossref","unstructured":"Erritzoe D Barba T Benway T et al. (2026) A short-acting psychedelic intervention for major depressive disorder: A phase IIa randomized placebo-controlled trial. Nature Medicine 32(2): 591\u2013598. https:\/\/doi.org\/10.1038\/s41591-025-04154-z","DOI":"10.1038\/s41591-025-04154-z"},{"key":"e_1_3_2_19_1","doi-asserted-by":"crossref","unstructured":"Falchi-Carvalho M Palhano-Fontes F Wie\u00dfner I et al. (2025) Rapid and sustained antidepressant effects of vaporized N N-dimethyltryptamine: A phase 2a clinical trial in treatment-resistant depression. Neuropsychopharmacology 50(6): 895\u2013903. https:\/\/doi.org\/10.1038\/s41386-025-02091-6","DOI":"10.1038\/s41386-025-02091-6"},{"key":"e_1_3_2_20_1","doi-asserted-by":"crossref","unstructured":"Falchi-Carvalho M Wie\u00dfner I Silva SRB et al. (2024) Safety and tolerability of inhaled N N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial. European Neuropsychopharmacology 80: 27\u201335. https:\/\/doi.org\/10.1016\/j.euroneuro.2023.12.006","DOI":"10.1016\/j.euroneuro.2023.12.006"},{"key":"e_1_3_2_21_1","volume-title":"Psychedelic Drugs: Considerations for Clinical Investigations","author":"FDA","year":"2023","unstructured":"FDA (2023) Psychedelic Drugs: Considerations for Clinical Investigations. U.S. Food and Drug Administration."},{"key":"e_1_3_2_22_1","doi-asserted-by":"crossref","unstructured":"Good M Benway T Joel Z et al. (2023) Pharmacokinetics of N N-dimethyltryptamine fumarate in humans. European Journal of Drug Metabolism and Pharmacokinetics 48(3): 311\u2013327. https:\/\/doi.org\/10.1007\/s13318-023-00822-y","DOI":"10.1007\/s13318-023-00822-y"},{"key":"e_1_3_2_23_1","doi-asserted-by":"crossref","unstructured":"Goodwin GM Aaronson ST Dunlop BW et al. (2022) The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: Results from a phase IIb randomised controlled trial. Neuroscience Applied 1: 100511. https:\/\/doi.org\/10.1007\/s00213-023-06432-5","DOI":"10.1016\/j.nsa.2022.100511"},{"key":"e_1_3_2_24_1","doi-asserted-by":"crossref","unstructured":"Gouzoulis-Mayfrank E Heekeren K Neukirch A et al. (2005) Psychological effects of (S)-ketamine and N N-dimethyltryptamine (DMT): A double-blind cross-over study in healthy volunteers. Pharmacopsychiatry 38(6): 301\u2013311. https:\/\/doi.org\/10.1055\/s-2005-916185","DOI":"10.1055\/s-2005-916185"},{"key":"e_1_3_2_25_1","doi-asserted-by":"crossref","unstructured":"Groeneveld GJ Hay JL Van Gerven JM (2016) Measuring blood-brain barrier penetration using the NeuroCart a CNS test battery. Drug discovery Today: Technologies 20: 27\u201334. https:\/\/doi.org\/10.1016\/j.ddtec.2016.07.004","DOI":"10.1016\/j.ddtec.2016.07.004"},{"key":"e_1_3_2_26_1","doi-asserted-by":"crossref","unstructured":"Howes OD Thase ME Pillinger T (2022) Treatment resistance in psychiatry: State of the art and new directions. Molecular Psychiatry 27(1): 58\u201372. https:\/\/doi.org\/10.1038\/s41380-021-01200-3","DOI":"10.1038\/s41380-021-01200-3"},{"key":"e_1_3_2_27_1","doi-asserted-by":"crossref","unstructured":"Jobert M Wilson FJ Ruigt GSF et al. (2012) Guidelines for the recording and evaluation of pharmaco-EEG data in man: The International Pharmaco-EEG Society (IPEG). Neuropsychobiology 66(4): 201\u2013220. https:\/\/doi.org\/10.1159\/000343478","DOI":"10.1159\/000343478"},{"key":"e_1_3_2_28_1","doi-asserted-by":"crossref","unstructured":"Johnson MW Richards WA Griffiths RR (2008) Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology 22(6): 603\u2013620. https:\/\/doi.org\/10.1159\/000343478","DOI":"10.1177\/0269881108093587"},{"key":"e_1_3_2_29_1","doi-asserted-by":"crossref","unstructured":"Kaplan J Mandel LR Stillman R et al. (1974) Blood and urine levels of N N-dimethyltryptamine following administration of psychoactive dosages to human subjects. Psychopharmacologia 38(3): 239\u2013245. https:\/\/doi.org\/10.1007\/BF00421376","DOI":"10.1007\/BF00421376"},{"key":"e_1_3_2_30_1","doi-asserted-by":"crossref","unstructured":"Kuznetsova A Brockhoff PB Christensen RHB (2017) lmerTest package: Tests in linear mixed effects models. Journal of Statistical Software 82(13): 1\u201326. https:\/\/doi.org\/10.3389\/fpsyg.2025.1697362","DOI":"10.18637\/jss.v082.i13"},{"key":"e_1_3_2_31_1","doi-asserted-by":"crossref","unstructured":"Layzell M Rands P Good M et al. (2023) Discovery and in vitro characterization of SPL028: Deuterated N N-dimethyltryptamine. ACS Medicinal Chemistry Letters 14(9): 1216\u20131223. https:\/\/doi.org\/10.1021\/acsmedchemlett.3c00143","DOI":"10.1021\/acsmedchemlett.3c00143"},{"key":"e_1_3_2_32_1","doi-asserted-by":"crossref","unstructured":"Luan LX Eckern\u00e4s E Ashton M et al. (2024) Psychological and physiological effects of extended DMT. Journal of Psychopharmacology 38(1): 56\u201367. https:\/\/doi.org\/10.1177\/02698811231196877","DOI":"10.1177\/02698811231196877"},{"key":"e_1_3_2_33_1","doi-asserted-by":"crossref","unstructured":"Mueller MJ Aicher HD Dornbierer DA et al. (2024) Pharmacokinetics and pharmacodynamics of an innovative psychedelic N N-dimethyltryptamine\/harmine formulation in healthy participants: A randomized controlled trial. The International Journal of Neuropsychopharmacology 28(1): pyaf001. https:\/\/doi.org\/10.1093\/ijnp\/pyaf001","DOI":"10.1093\/ijnp\/pyaf001"},{"key":"e_1_3_2_34_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2020","unstructured":"R Core Team (2020) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing."},{"key":"e_1_3_2_35_1","doi-asserted-by":"crossref","unstructured":"Raison CL Sanacora G Woolley J et al. (2023) Single-dose psilocybin treatment for major depressive disorder a randomized clinical trial. JAMA 330(9): 843\u2013853. https:\/\/doi.org\/10.1001\/jama.2023.14530.","DOI":"10.1001\/jama.2023.14530"},{"key":"e_1_3_2_36_1","doi-asserted-by":"crossref","unstructured":"Rosenberg DE Isbell H Miner EJ (1963) Comparison of a placebo N-dimethyltryptamine and 6-hydroxy-N-dimethyltryptamine in man. Psychopharmacologia 4(1): 39\u201342. https:\/\/doi.org\/10.1007\/BF00429362","DOI":"10.1007\/BF00429362"},{"key":"e_1_3_2_37_1","doi-asserted-by":"crossref","unstructured":"Rosenberg DE Isbell H Miner EJ et al. (1964) The effect of N N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide. Psychopharmacologia 5: 217\u2013227. https:\/\/doi.org\/10.1007\/BF00413244","DOI":"10.1007\/BF00413244"},{"key":"e_1_3_2_38_1","doi-asserted-by":"crossref","unstructured":"Sherman MM Tarantino PM Morrison DN et al. (2022) A double-blind randomized two-part two-period crossover study to evaluate the pharmacokinetics of caffeine versus d9-caffeine in healthy subjects. Regulatory Toxicology and Pharmacology 133: 105194. https:\/\/doi.org\/10.1016\/j.yrtph.2022.105194","DOI":"10.1016\/j.yrtph.2022.105194"},{"key":"e_1_3_2_39_1","doi-asserted-by":"crossref","unstructured":"Strassman RJ (1996) Human psychopharmacology of N N-dimethyltryptamine. Behavioural Brain Research 73(1\u20132): 121\u2013124. https:\/\/doi.org\/10.1016\/0166-4328(96)00081-2","DOI":"10.1016\/0166-4328(96)00081-2"},{"key":"e_1_3_2_40_1","doi-asserted-by":"crossref","unstructured":"Strassman RJ Qualls CR (1994) Dose-response study of N N-dimethyltryptamine in humans: I. neuroendocrine autonomic and cardiovascular effects. Archives of General Psychiatry 51(2): 85\u201397. https:\/\/doi.org\/10.1016\/0166-4328(96)00081-2","DOI":"10.1001\/archpsyc.1994.03950020009001"},{"key":"e_1_3_2_41_1","doi-asserted-by":"crossref","unstructured":"Strassman RJ Qualls CR Uhlenhuth EH et al. (1994) Dose-response study of N N-Dimethyltryptamine in humans II: Subjective effects and preliminary results of a new rating scale. Archives Of General Psychiatry 51: 98\u2013108. https:\/\/doi.org\/10.1001\/archpsyc.1994.03950020022002","DOI":"10.1001\/archpsyc.1994.03950020022002"},{"key":"e_1_3_2_42_1","doi-asserted-by":"crossref","unstructured":"Strassman RJ Qualls CR Berg LM (1996) Differential tolerance to biological and subjective effects of four closely spaced doses of N N-Dimethyltryptamine in humans. Biological Psychiatry 39(9): 784\u2013795. https:\/\/doi.org\/10.1016\/0006-3223(95)00200-6","DOI":"10.1016\/0006-3223(95)00200-6"},{"key":"e_1_3_2_43_1","doi-asserted-by":"crossref","unstructured":"Studerus E Gamma A Vollenweider FX (2010) Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS ONE 5(8): e12412. https:\/\/doi.org\/10.1016\/0006-3223(95)00200-6","DOI":"10.1371\/journal.pone.0012412"},{"key":"e_1_3_2_44_1","doi-asserted-by":"crossref","unstructured":"Timmermann C Roseman L Schartner M et al. (2019) Neural correlates of the DMT experience assessed with multivariate EEG. Scientific Reports 9(1): 16324. https:\/\/doi.org\/10.1038\/s41598-019-51974-4","DOI":"10.1038\/s41598-019-51974-4"},{"key":"e_1_3_2_45_1","doi-asserted-by":"crossref","unstructured":"Timmermann C Roseman L Haridas S et al. (2023) Human brain effects of DMT assessed via EEG-fMRI. Proceedings of the National Academy of Sciences of the United States of America 120(13): e2218949120. https:\/\/doi.org\/10.1073\/pnas.2218949120","DOI":"10.1073\/pnas.2218949120"},{"key":"e_1_3_2_46_1","doi-asserted-by":"crossref","unstructured":"Timmins GS (2014) Deuterated drugs: Where are we now? Expert Opinion on Therapeutic Patents 24(10): 1067\u20131075. https:\/\/doi.org\/10.1517\/13543776.2014.943184","DOI":"10.1517\/13543776.2014.943184"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811261473451"},{"key":"e_1_3_2_48_1","doi-asserted-by":"crossref","unstructured":"van der Heijden KV Otto ME Schoones JW et al. (2025) Clinical pharmacokinetics of N N-dimethyltryptamine (DMT): A systematic review and post-hoc analysis. Clinical Pharmacokinetics 64(2): 215\u2013227. https:\/\/doi.org\/10.1007\/s40262-024-01450-8","DOI":"10.1007\/s40262-024-01450-8"},{"key":"e_1_3_2_49_1","doi-asserted-by":"crossref","unstructured":"van Steveninck AL van Berckel BN Schoemaker RC et al. (1999) The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. Journal of Psychopharmacology 13(1): 10\u201317. https:\/\/doi.org\/10.1177\/026988119901300102","DOI":"10.1177\/026988119901300102"},{"key":"e_1_3_2_50_1","doi-asserted-by":"crossref","unstructured":"Vogt SB Ley L Erne L et al. (2023) Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants. Translational Psychiatry Psychiatry 13(1): 172. https:\/\/doi.org\/10.1038\/s41398-023-02477-4","DOI":"10.1038\/s41398-023-02477-4"},{"key":"e_1_3_2_51_1","doi-asserted-by":"crossref","unstructured":"von Rotz R Schindowski EM Jungwirth J et al. (2023) Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled double-blind randomised clinical trial. eClinicalMedicine 56: 101809. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101841","DOI":"10.1016\/j.eclinm.2022.101809"},{"key":"e_1_3_2_52_1","doi-asserted-by":"crossref","unstructured":"Yao Y Guo D Lu T-S et al. (2024) Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry Research 335: 115886. https:\/\/doi.org\/10.1016\/j.psychres.2024.115886","DOI":"10.1016\/j.psychres.2024.115886"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261478616","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261478616","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261478616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T03:39:22Z","timestamp":1788665962000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261478616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":51,"alternative-id":["10.1177\/02698811261478616"],"URL":"https:\/\/doi.org\/10.1177\/02698811261478616","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"02698811261478616"}}